These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30604893)

  • 1. Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2.
    Lu X; Zhang X; Zhang Y; Zhang K; Zhan C; Shi X; Li Y; Zhao J; Bai Y; Wang Y; Nie H; Li Y
    Mol Carcinog; 2019 May; 58(5):749-759. PubMed ID: 30604893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
    Fujiwara N; Nakagawa H; Enooku K; Kudo Y; Hayata Y; Nakatsuka T; Tanaka Y; Tateishi R; Hikiba Y; Misumi K; Tanaka M; Hayashi A; Shibahara J; Fukayama M; Arita J; Hasegawa K; Hirschfield H; Hoshida Y; Hirata Y; Otsuka M; Tateishi K; Koike K
    Gut; 2018 Aug; 67(8):1493-1504. PubMed ID: 29437870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling.
    Violante S; Ijlst L; van Lenthe H; de Almeida IT; Wanders RJ; Ventura FV
    Biochim Biophys Acta; 2010 Sep; 1802(9):728-32. PubMed ID: 20538056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octanoate is differentially metabolized in liver and muscle and fails to rescue cardiomyopathy in CPT2 deficiency.
    Pereyra AS; Harris KL; Soepriatna AH; Waterbury QA; Bharathi SS; Zhang Y; Fisher-Wellman KH; Goergen CJ; Goetzman ES; Ellis JM
    J Lipid Res; 2021; 62():100069. PubMed ID: 33757734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient.
    Violante S; Ijlst L; Te Brinke H; Koster J; Tavares de Almeida I; Wanders RJ; Ventura FV; Houten SM
    Biochim Biophys Acta; 2013 Sep; 1831(9):1467-74. PubMed ID: 23850792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Muscle Carnitine Palmitoyltransferase 2 Prevents Diet-Induced Obesity and Insulin Resistance despite Long-Chain Acylcarnitine Accumulation.
    Pereyra AS; Rajan A; Ferreira CR; Ellis JM
    Cell Rep; 2020 Nov; 33(6):108374. PubMed ID: 33176143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
    Violante S; Ijlst L; Te Brinke H; Tavares de Almeida I; Wanders RJ; Ventura FV; Houten SM
    FASEB J; 2013 May; 27(5):2039-44. PubMed ID: 23322164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.
    Liu Y; Wang F; Yan G; Tong Y; Guo W; Li S; Qian Y; Li Q; Shu Y; Zhang L; Zhang Y; Xia Q
    Cancer Lett; 2024 Jul; 595():217006. PubMed ID: 38823763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
    González-Romero F; Mestre D; Aurrekoetxea I; O'Rourke CJ; Andersen JB; Woodhoo A; Tamayo-Caro M; Varela-Rey M; Palomo-Irigoyen M; Gómez-Santos B; de Urturi DS; Núñez-García M; García-Rodríguez JL; Fernández-Ares L; Buqué X; Iglesias-Ara A; Bernales I; De Juan VG; Delgado TC; Goikoetxea-Usandizaga N; Lee R; Bhanot S; Delgado I; Perugorria MJ; Errazti G; Mosteiro L; Gaztambide S; Martinez de la Piscina I; Iruzubieta P; Crespo J; Banales JM; Martínez-Chantar ML; Castaño L; Zubiaga AM; Aspichueta P
    Cancer Res; 2021 Jun; 81(11):2874-2887. PubMed ID: 33771899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate specificity of human carnitine acetyltransferase: Implications for fatty acid and branched-chain amino acid metabolism.
    Violante S; Ijlst L; Ruiter J; Koster J; van Lenthe H; Duran M; de Almeida IT; Wanders RJ; Houten SM; Ventura FV
    Biochim Biophys Acta; 2013 Jun; 1832(6):773-9. PubMed ID: 23485643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.
    Huang Q; Tan Y; Yin P; Ye G; Gao P; Lu X; Wang H; Xu G
    Cancer Res; 2013 Aug; 73(16):4992-5002. PubMed ID: 23824744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma.
    Enooku K; Nakagawa H; Fujiwara N; Kondo M; Minami T; Hoshida Y; Shibahara J; Tateishi R; Koike K
    Sci Rep; 2019 Jul; 9(1):10663. PubMed ID: 31337855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental regulation and localization of carnitine palmitoyltransferases (CPTs) in rat brain.
    Jernberg JN; Bowman CE; Wolfgang MJ; Scafidi S
    J Neurochem; 2017 Aug; 142(3):407-419. PubMed ID: 28512781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKD1 correlates with a poor prognosis and inhibits cell proliferation by inducing p53 expression in hepatocellular carcinoma.
    Zhang S; Li J; Wang X
    Tumour Biol; 2016 Oct; 37(10):14059-14067. PubMed ID: 27507614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
    Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
    Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of mitochondria long-chain fatty acid oxidation impairs skeletal muscle contractility by disrupting myofibril structure and calcium homeostasis.
    Pereyra AS; Fernandez RF; Amorese A; Castro JN; Lin CT; Spangenburg EE; Ellis JM
    Mol Metab; 2024 Nov; 89():102015. PubMed ID: 39182841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of CPT2 promotes tumorigenesis and chemoresistance to cisplatin in hepatocellular carcinoma.
    Lin M; Lv D; Zheng Y; Wu M; Xu C; Zhang Q; Wu L
    Onco Targets Ther; 2018; 11():3101-3110. PubMed ID: 29872321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases.
    Zhou L; Wang Q; Yin P; Xing W; Wu Z; Chen S; Lu X; Zhang Y; Lin X; Xu G
    Anal Bioanal Chem; 2012 Apr; 403(1):203-13. PubMed ID: 22349331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells.
    Djouadi F; Aubey F; Schlemmer D; Bastin J
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1791-7. PubMed ID: 15613406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carnitine palmitoyltransferase 2 deficiency: the time-course of blood and urinary acylcarnitine levels during initial L-carnitine supplementation.
    Hori T; Fukao T; Kobayashi H; Teramoto T; Takayanagi M; Hasegawa Y; Yasuno T; Yamaguchi S; Kondo N
    Tohoku J Exp Med; 2010 Jul; 221(3):191-5. PubMed ID: 20543534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.